WISE develops implantable, stretchable electronic electrodes using its proprietary Supersonic Technology to create ultra-thin elastomeric foils that aim to improve tissue conformability, softness, adhesion and signal sensing versus rigid electrodes. Its lead product in the round, the Heron lead, is a spinal cord stimulation device designed to deliver targeted directional stimulation via a minimally invasive percutaneous implant technique and to combine the precision of paddle leads with the procedural ease of cylindrical leads. WISE also markets the WISE Cortical Strip, a soft and stretchable electrode for intraoperative neurophysiological monitoring that has CE marking under MDR, FDA clearance, and is commercially available in Europe, the U.S., and Australia. The company plans to use the Series D proceeds to complete the Heron lead’s regulatory certification pathway, fund a first-in-human study, and scale commercialization of its electrode portfolio across target markets. The company positions its technology to support higher energy efficiency, improved anatomical coverage, better neural signal sensing, and reduced lead migration. The financing coincided with governance updates, including the appointment of Laura Iris Ferro as Chairperson and the addition of Giuseppe Corvino to the board.

Total raised

$90M

Funding rounds

7

Latest round

Series D

Latest activity

Jun 2026